Industry News
Biotechnology Industry News
The Swiss drugmaker has plucked an…
The Swiss drugmaker has plucked an experienced scientist from Down Under to lead its early research efforts. Hematologist Mark Dawson, M.D., Ph.D., an expert in cancer epigenetics, will now head up Roche’s pharma research and
Novartis has jettisoned an…
Novartis has jettisoned an anti-cancer protein from its pipeline after the molecule failed to shrink tumors in 30 patients with advanced disease.
Breaking ground: iRegene’s…
Breaking ground: iRegene’s NouvNeu001 hits first U.S. dosing in Parkinson’s Phase IIa, while NouvNeu004 starts enrollment in China MSA trial. Pushing forward off-the-shelf iPSC therapies on a global scale.
Politico has reported that the…
Politico has reported that the White House isn’t happy with the FDA’s recent actions surrounding vaccines, fueling public scrutiny of internal decision-making at the regulator.
Johnson & Johnson has paused…
Johnson & Johnson has paused further enrollment in a phase 2b trial of its AC Immune-partnered Alzheimer’s disease candidate, leaving analysts to speculate that recruitment challenges may be the culprit.
Sanofi has backed the $75 million…
Sanofi has backed the $75 million series B of a rhinovirus-focused biotech helmed by a former FDA acting commissioner.
Demyelinating diseases, including…
Demyelinating diseases, including multiple sclerosis (MS) and Charcot-Marie-Tooth (CMT) disease, present a substantial and escalating burden. Each of these conditions afflicts approximately three million individuals worldwide.
In a deal with Theriva Biologics…
In a deal with Theriva Biologics potentially worth as much as $36 million, Rasayana Therapeutics has gained a gastrointestinal asset called SYN-020.
Only a couple of months ago,…
Only a couple of months ago, Sensei Biotherapeutics was laying off staff and mulling winding down the company. But the biotech has found a new lease on life—and a new lead drug—via a merger with
Unnatural Products is proving to…
Unnatural Products is proving to be a natural at securing partnerships, this time linking up with Novartis in a deal that could garner up to $1.7 billion in biobucks.
The FDA has accepted Moderna’s…
The FDA has accepted Moderna’s revised influenza vaccine filing days after controversially refusing to review the original submission, putting the biotech on track to win approval in time for the 2026-27 flu season.
EIR Biopharma is hoping to bring…
EIR Biopharma is hoping to bring in $17.1 million from an IPO on the New York Stock Exchange that could fund development of its preclinical eye disease drug.
Eli Lilly is paying $100 million…
Eli Lilly is paying $100 million upfront for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection.
A new entrant in the race to…
A new entrant in the race to shepherd antibodies for Alzheimer’s disease across the blood-brain barrier has emerged. Korsana Biosciences has catapulted out of stealth with $175 million and designs for a 2027 clinical debut.
Boehringer Ingelheim is discarding…
Boehringer Ingelheim is discarding an inhaled gene therapy designed to treat cystic fibrosis after terminating a phase 1/2 trial.
Japan-based cell therapy company…
Japan-based cell therapy company Innovacell is planning to end a drought of biotech IPOs on the Tokyo Stock Exchange next week, the business’ CEO has confirmed.
Cyrano Therapeutics is savoring a…
Cyrano Therapeutics is savoring a phase 2 victory. With the Flavor study hitting its primary endpoint, the biotech is preparing to take its treatment for persistent smell loss into phase 3 in the second half
Compass Pathways has reported…
Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the biotech’s share price up 30% and teeing up talks about filing for approval.
As Sanofi attempts to bounce back…
As Sanofi attempts to bounce back from a tough year of clinical readouts, the French pharma has touted longer-term phase 2 data for its bowel disease bet as showing the Teva-partnered prospect remains a “key
Gilead Sciences has secured…
Gilead Sciences has secured another synthetic lethal therapy, handing $80 million upfront for the global rights to a clinic-ready cancer drug from China’s Genhouse Bio.